Clinical Trial

Prospective Evaluation of De-Escalation From antiCD-20 Therapies to Dimethyl Fumarate (Tecfidera) or Diroximel Fumarate (Vumerity)

Name: Prospective Evaluation of De-Escalation From antiCD-20 Therapies to Dimethyl Fumarate (Tecfidera) or Diroximel Fumarate (Vumerity) — clinical trial record (NCT07757568)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Active, Not Recruiting

View on ClinicalTrials.gov →

Summary

The investigators propose a multi-center pilot study, which aims to evaluate safety and efficacy of fumarates as de-escalation therapy in clinically stable MS patients previously treated with anti-CD20 therapy.

Trial Details

NCT Number	NCT07757568
Lead Sponsor	University of Colorado, Denver
Conditions	Multiple Sclerosis (MS) Relapsing Remitting
Enrollment	11 participants
Start Date	2023-03-07
Primary Completion	2026-09-01 (estimated)
Study Completion	2026-11-07 (estimated)
Updated on ClinicalTrials.gov	2026-08-11